DRY PLATELET PREPARATIONS FOR USE IN DIAGNOSTICS

• US 20110183311A1
• Filed: 01/27/2010
• Published: 07/28/2011
• Est. Priority Date: 01/27/2010
• Status: Abandoned Application

• Current Assignee: Alan Rudolph, Cindy Orser, David Ho, Keith A. Moskowitz
• Original Assignee: Alan Rudolph, Cindy Orser, David Ho, Keith A. Moskowitz
• Inventors: Orser, Cindy, Moskowitz, Keith A., Rudolph, Alan, HO, David
• Application Number:
  US12/694,504
• Publication Number:
  US 20110183311A1
• Time in Patent Office: Days
• US Class Current: 435/2
• CPC Class Codes: G01N 2800/224 Haemostasis or coagulation
• CPC Class Codes: G01N 33/86 involving blood coagulating time or factors, or their receptors

Abstract

The present invention provides compositions comprising freeze-dried platelets, microparticles, or both for use as a diagnostic for blood coagulation function. The invention also provides methods of diagnosing or monitoring blood coagulation function, including diagnosing or monitoring blood coagulation diseases and disorders. Kits for performing the methods of the invention are also provided.

Claims

1. An in vitro composition comprising freeze-dried platelets and whole blood, blood plasma, or a component of whole blood or blood plasma.

2. The composition of claim 1, comprising freeze-dried platelets and fresh platelets.

3. The composition of claim 1, wherein the freeze-dried platelets are reconstituted.

4. The composition of claim 1, wherein the freeze-dried platelets are platelets from a public blood source.

5. The composition of claim 1, wherein the freeze-dried platelets are from a patient undergoing, or scheduled to undergo, a therapy that might affect blood clotting activity of that patient.

6. A method of determining the blood clotting capability of a sample comprising blood or a blood component, said method comprising

combining freeze-dried platelets with fresh blood or a blood component to create a mixture;

and

assaying the mixture for one or more biological or biochemical functions indicative of one or more blood clotting functions.

7. The method of claim 6, wherein the method is a method of diagnosing a disease or disorder of the blood clotting system.

8. The method of claim 6, wherein the freeze-dried platelets are obtained from a patient having, or suspected of having, a defect in his blood clotting system.

9. The method of claim 6, wherein the fresh blood or blood component is obtained from a patient having, or suspected of having, a defect in his blood clotting system.

10. The method of claim 6, wherein the method is a method of monitoring the progression of a disease or disorder of the blood clotting system.

11. The method of claim 10, wherein the method comprises

combining freeze-dried platelets obtained from a patient at a time point zero with platelets removed from the patient at a later time point to make a mixture, and

determining the blood clotting ability of the mixture.

12. The method of claim 11, further comprising removing a second amount of platelets at a second later time point, combining them with the freeze-dried platelets, and determining the blood clotting ability of the mixture.

13. The method of claim 6, which is a method of monitoring the effects of a treatment regimen for a patient on the blood clotting system of that patient.

14. A kit comprising freeze-dried platelets and at least one substance that affects the blood clotting system.

15. The kit of claim 14, wherein the substance is a drug.

16. The kit of claim 15, wherein the drug has anti-platelet activity.

17. The kit of claim 15, wherein the drug reduces the ability of a patient'"'"'s blood to clot.

18. The kit of claim 14, wherein the freeze-dried platelets are platelets from a public blood source.

19. The kit of claim 14, comprising multiple containers containing freeze-dried platelets.

20. The kit of claim 14, comprising multiple containers containing two or more different substances.